Rock Creek Pharmaceuticals, Inc.
RCPIQ
Other OTC0.00
USD
- -
- -
Return %
Stock
S&P500
1Y
9,900.00
19.01
3Y
-80.00
65.49
5Y
-83.50
72.21
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Michael John Mullan MBBS (M.D.,),
- Full Time Employees
- 5
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 2040 Whitfield Avenue Sarasota FL United States of America 34243
- IPO Date
- Feb 27, 1998
- Website
- rockcreekpharmaceuticals.com
- Similar Companies
- Business
- Rock Creek Pharmaceuticals, Inc. (RCPIQ) is a pharmaceutical development company that focuses on the discovery, development, and commercialization of therapies for chronic inflammatory diseases and neurologic disorders; its lead compound is anatabine citrate, a small molecule cholinergic agonist exhibiting anti-inflammatory characteristics distinct from biologics, steroids, and non-steroidal anti-inflammatories; the company targets applications in dermatological skin diseases such as psoriasis and eczema, clinical immunology, neurological disease, and behavioral health. Founded in 1985 and formerly known as Star Scientific, Inc., which changed its name in June 2014, Rock Creek Pharmaceuticals is headquartered in Sarasota, Florida, with prior operations including a regulatory office in Washington, D.C.. The company filed for Chapter 7 liquidation under bankruptcy on September 27, 2016, with assets of approximately $35,000 against liabilities exceeding $21 million, and ceased operations as confirmed by a December 8, 2020, out-of-business filing. No recent partnerships, funding rounds, acquisitions, new product launches, or operational expansions have been reported since its bankruptcy liquidation.